Dallas, Texas – AccelSPINE received FDA clearance on its Picasso II system, which is designed to enhance the spinal implant experience for surgeons and patients.
"Picasso II is the next generation of minimally invasive spine systems. It incorporates an easy-to-use, double-lead thread, and self-tapping screw with an innovative rod-delivery system to increase implant efficiency," stated Daniel Chon, AccelSPINE president and CEO.
Picasso II is intended to immobilize and stabilize spinal segments in skeletally mature patients as a supplement to fusion during the treatment of acute and chronic instabilities or deformities of the upper or lower spine, or the sacral (tail-bone) region. The system is a continuation of the Picasso product line – Picasso I received FDA clearance in 2012. Picasso I is a minimally invasive system featuring a broad selection of screw/rod delivery instruments and implants.
"The difference between Picasso I and Picasso II is the double-lead thread and self-tapping, anodized screw that streamlines the implant process. This is an evolutionary system that was designed based on input from our surgeons. We continually ask our surgeons for feedback on our products so that we can bring to market the best and most innovative products possible," said Estella Baytan, vice president of marketing and clinical operations for AccelSPINE.
Minimally invasive spine surgery vs. open-back
Minimally invasive spine surgery is designed to utilize smaller incisions and special tools in hopes of reducing tissue damage. Minimally invasive options may result in fewer or smaller scars, reduced blood loss, less pain and a shorter recovery time for patients than they would have experienced with traditional, open-backed surgery. In addition, minimally invasive surgery has been reported to "minimize cutting to muscles, tendons and other normal tissues that aren't directly involved with the back disorders."